April 17th 2025
These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.
Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy
December 9th 2012Richard T. Hoppe, MD, Professor of Radiation Oncology - Radiation Therapy, Stanford School of Medicine, discussed the current role and utility of radiation therapy in patients with early stage Hodgkins Lymphoma when compared to conventional chemotherapy.
Read More
Value of Survival Gains in Chronic Myeloid Leukemia
Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.
Read More
Payer Management of Oncology: An In-Depth Look
November 21st 2012On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.
Read More
Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study
Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.
Read More
Payer Management of Oncology: An In-Depth Look
November 19th 2012On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.
Read More
Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care
November 19th 2012Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.
Read More
Automated Telephone Calls to Enhance Colorectal Cancer Screening: Economic Analysis
Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.
Read More
Mark Fendrick, MD, Discusses Value-Based Insurance Design
November 19th 2012Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.
Read More
Michael Chernew, PhD, Discusses Challenges in Oncology Management
November 16th 2012Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.
Read More
Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships
November 16th 2012Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.
Read More
Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program
Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.
Read More
Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market
October 11th 2012In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.
Read More